Daily Endocrinology Research Analysis
Analyzed 107 papers and selected 3 impactful papers.
Summary
Three impactful endocrinology studies stood out today. A Nature Communications translational study uncovers a diet–exosome microRNA axis linking capsaicin intake to idiopathic short stature and demonstrates a corrective exosome-based strategy in preclinical models. Diabetes Care triangulates clamp phenotyping and Mendelian randomization to support a causal link between insulin resistance and reduced lung function, while Frontiers in Endocrinology introduces and externally validates data-driven subgroups of renin-independent aldosteronism with distinct cardiovascular risks and therapeutic implications.
Research Themes
- Diet–microbiome–exosome axis in growth disorders
- Insulin resistance as a driver of pulmonary dysfunction in diabetes
- Precision phenotyping in renin-independent aldosteronism for risk stratification
Selected Articles
1. Capsaicin diet drives gut inflammation and exosomal miR-17-3p elevation in idiopathic short stature.
This translational study links a capsaicin-rich diet to idiopathic short stature via exosomal miR-17-3p that suppresses ZNF148/SOS1 signaling and impairs chondrocyte proliferation. A rat model recapitulated the phenotype with normal GH/IGF-1 but elevated exosomal miR-17-3p and gut inflammation, and engineered anti–miR-17-3p exosomes plus local GH restored growth plate function.
Impact: It reveals a diet–exosome–growth axis with a specific microRNA mediator and demonstrates a corrective preclinical strategy, potentially transforming diagnosis and treatment of ISS in high–capsaicin-intake populations.
Clinical Implications: While not practice-changing yet, the study suggests assessing dietary capsaicin exposure and considering exosomal miR-17-3p as a biomarker for ISS risk stratification. It also motivates clinical trials testing dietary modification and miR-17-3p–targeted strategies alongside GH therapy.
Key Findings
- Exosomal hsa-miR-17-3p is elevated in children with idiopathic short stature and suppresses ZNF148/SOS1 signaling, impairing growth signaling and chondrocyte proliferation.
- A capsaicin-rich diet in rats induces mild gut inflammation and increases miR-17-3p in intestinal and plasma exosomes with normal GH/IGF-1 levels, recapitulating ISS-like features.
- Engineered anti–miR-17-3p exosomes combined with local growth hormone restored growth plate function in preclinical models.
- Fecal samples from ISS children showed elevated miR-17-3p and inflammatory markers, linking spicy diets to ISS pathogenesis.
Methodological Strengths
- Multi-system translational approach integrating human exosome profiling, dietary animal models, and mechanistic rescue experiments.
- Molecular pathway mapping (ZNF148/SOS1) with functional validation using engineered exosomes and growth plate readouts.
Limitations
- Human component lacks detailed sample size and is observational, limiting causal inference.
- Generalizability across diverse diets and populations is uncertain; preclinical therapeutic data require clinical translation.
Future Directions: Prospective dietary-intervention trials in ISS-prone regions; validation of exosomal miR-17-3p as a biomarker; early-phase trials of miR-17-3p–targeting strategies in combination with GH.
Idiopathic short stature (ISS) remains a major pediatric challenge with unclear causes and inconsistent responses to growth hormone therapy. Here we show that plasma exosomes from children with ISS contain elevated hsa-miR-17-3p that disrupts growth signaling and impairs cartilage cell proliferation. Elevated miR-17-3p suppresses ZNF148/SOS1 signaling, linking molecular dysfunction to dietary exposure in ISS. To investigate environmental triggers, we developed a capsaicin-rich diet rat model that recapitulates ISS, showing normal Gh/Igf-1 levels but elevated plasma miR-17-3p. The diet induced mild gut inflammation, increasing miR-17-3p in intestinal and plasma exosomes. Fecal samples from ISS children exhibited similar elevations in miR-17-3p and inflammatory markers, linking spicy diets to ISS pathogenesis. Finally, engineered exosomes designed to silence miR-17-3p, combined with localized growth hormone therapy, restored growth plate function. These findings uncover a diet-driven exosome axis underlying ISS and suggest new therapeutic strategies for children in high-capsaicin regions.
2. Metabolic Factors Modulating the Connection Between Diabetes and Pulmonary Alterations.
In a cross-sectional analysis with clamp phenotyping, higher insulin sensitivity and clearance were associated with higher FEV1/FVC, whereas type 2 diabetes showed lower spirometric indices. Mendelian randomization supported a causal effect of insulin resistance (HOMA-IR) on reduced FEV1, highlighting hyperinsulinemia-related mechanisms.
Impact: By triangulating detailed metabolic phenotyping with Mendelian randomization, the study moves beyond association to causal inference linking insulin resistance to pulmonary impairment in diabetes.
Clinical Implications: Consider spirometric screening in adults with diabetes, especially with severe insulin resistance, and prioritize interventions that reduce insulin resistance and hyperinsulinemia (e.g., lifestyle, insulin-sensitizers). Monitor pulmonary function where high insulin doses are required.
Key Findings
- Higher insulin sensitivity (M value) and insulin clearance correlated with higher FEV1 and FVC (all β > 0.18 for M; β = 0.05 for clearance).
- Type 2 diabetes had lower FEV1/FVC compared with type 1 diabetes and controls; in type 1 diabetes, higher daily insulin dose associated with lower FEV1 (β = -0.21).
- Mendelian randomization indicated a causal association between HOMA-IR and reduced FEV1 (β = -0.13, P = 0.0018).
Methodological Strengths
- Use of Botnia clamp phenotyping (insulin sensitivity, secretion, clearance) to robustly quantify metabolic status.
- Causal triangulation via Mendelian randomization with large external cohorts (MAGIC; UKHLS).
Limitations
- Cross-sectional design in GDS limits temporal inference; residual confounding possible.
- Generalizability beyond the studied cohorts requires validation; MR pertains to HOMA-IR instrument only.
Future Directions: Interventional trials testing whether improving insulin sensitivity/clearance preserves or improves lung function; mechanistic studies on hyperinsulinemia effects on airway and parenchyma.
OBJECTIVE: Type 1 and 2 diabetes have been variably associated with reduced forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC), but mechanisms remain unclear. This study examined the role of glucose and insulin metabolism for pulmonary function across diabetes (sub)types and normal glucose tolerance as the control (CON) in the German Diabetes Study (GDS) and assessed causality by Mendelian randomization (MR) analyses in independent cohorts. RESEARCH DESIGN AND METHODS: In GDS, 426 spirometry measurements of participants with type 1 diabetes, 482 of participants with type 2 diabetes, and 244 of CON were cross-sectionally analyzed after phenotyping, including Botnia clamps for insulin sensitivity (M value), secretion, and clearance. Associations between metabolic measures and lung function were assessed using generalized linear models, adjusting for confounders. MR analysis used data from the MAGIC (Meta-Analyses of Glucose and Insulin-Related Traits Consortium) consortium (HOMA-insulin resistance [IR], n = 37,037) and the UK Household Longitudinal Study (pulmonary function, n = 321,047). RESULTS: In GDS, higher M value (all β > 0.18, P < 0.0001) and insulin clearance (all β = 0.05, P < 0.050) were associated with higher FEV1 and FVC. Compared with type 1 diabetes and CON, type 2 diabetes had lower FEV1 and FVC, which associated with M value (all β > 0.17, P < 0.050). FEV1 was associated with daily insulin doses in type 1 diabetes (β = -0.21, P = 0.0006). FEV1 was associated with type 2 diabetes (β = -0.19, P = 0.0052), severe insulin resistant (β =-0.27, P = 0.039), and mild age-related diabetes (β = -0.23, P = 0.0033). MR supported a causal association between HOMA-IR and lower FEV1 (β = -0.13, P = 0.0018). CONCLUSIONS: Lower FEV1 and FVC in diabetes are linked to insulin resistance, impaired clearance, and higher insulin doses, all of which result in higher insulinemia and likely represent underlying pathogenic mechanisms.
3. Data-driven cluster analysis and external validation identify phenotypic subgroups in renin-independent aldosteronism with differential cardiovascular risk and therapeutic implications.
Unsupervised clustering revealed three reproducible phenotypes of renin-independent aldosteronism and was externally validated. A metabolically adverse cluster carried the greatest cardiovascular risk, followed by a high-aldosterone cluster, redefining risk drivers and informing therapeutic prioritization.
Impact: Provides a refined, validated classification that stratifies cardiovascular risk beyond aldosterone levels, enabling more precise therapeutic targeting in a heterogeneous endocrine hypertension phenotype.
Clinical Implications: Patients in the metabolically adverse or high-aldosterone clusters may benefit from tailored mineralocorticoid receptor antagonist strategies and aggressive cardiometabolic risk management; cluster assignment could inform monitoring intensity.
Key Findings
- Three reproducible clusters of renin-independent aldosteronism were identified and externally validated in the Framingham cohort.
- Cluster 2 exhibited the most severe metabolic abnormalities and the highest risks of cardiovascular disease, chronic heart failure, and atrial fibrillation.
- Cluster 3 had the highest aldosterone levels and elevated cardiovascular disease incidence, while both clusters 2 and 3 showed higher baseline blood pressure and left ventricular remodeling.
- Findings suggest metabolic dysfunction as a dominant cardiovascular risk driver in renin-independent aldosteronism, redefining risk paradigms.
Methodological Strengths
- Unsupervised clustering using 12 clinical parameters with external validation in an independent community cohort.
- Comprehensive outcome assessment including echocardiography, serum biomarkers, and clinical events.
Limitations
- Observational design limits causal inference and may be subject to selection or measurement biases.
- Treatment effects by cluster were not prospectively tested; follow-up duration details are not delineated in the abstract.
Future Directions: Prospective trials to test cluster-guided therapy (e.g., mineralocorticoid receptor antagonists, metabolic risk modification) and integration of omics for further phenotypic refinement.
BACKGROUND: Renin-independent aldosterone secretion contributes to aldosteronism and heightened cardiovascular risk, but renin-independent aldosteronism is highly heterogenous. A refined classification may assist in identifying individuals with distinct cardiovascular risk profiles and guide individualized treatment strategies. METHODS: Unsupervised hierarchical clustering was performed using 12 clinical parameters from patients with renin-independent aldosteronism in our registry cohort (n=404). The cluster centroids derived from the discovery cohort were fixed and applied to the Framingham Heart Study Third Generation cohort (n=417) for subject classification. The identified clusters were evaluated for their association with cardiovascular outcomes, assessed by echocardiographic parameters, serum biomarkers and cardiovascular event rates. RESULTS: Three replicable clusters of patients with renin-independent aldosteronism were identified. Patients in cluster 2 showed the most severe metabolic abnormalities with the highest lipid and glucose levels, while patients in cluster 3 displayed the highest aldosterone levels. Both clusters 2 and 3 showed elevated baseline blood pressure and left ventricular remodeling compared with cluster 1. Cluster 2 exhibited the highest risk of cardiovascular disease, chronic heart failure and atrial fibrillation, followed by cluster 3, which showed a higher incidence of cardiovascular disease compared with cluster 1. CONCLUSIONS: We identified 3 subgroups with differing degrees of target organ damage and cardiovascular risk. Our findings establish metabolic dysfunction, rather than aldosterone excess, as a potential dominant cardiovascular risk driver in RIA patients, defining a new risk paradigm. Patients with renin-independent aldosteronism with metabolic dysfunction or high aldosterone levels may benefit from mineralocorticoid receptor antagonists with different priorities for metabolic and cardiovascular protection. This new refined classification may help tailor optimal treatment strategies for patients with heterogenous renin-independent aldosteronism.